Local application of niclosamide would stand in contrast to the systemic delivery of chloroquine and hydroxychloroquine, which failed in clinical trials against COVID-19 (88) and were reported to be noneffective against SARS-CoV-2 infections of cells expressing transmembrane protease serine subtype 2 (TMPRSS2) (89). This evidence concerns the gene TMPRSS2 and COVID-19.